Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, marketing, import/export, and wholesale of pharmaceuticals, diagnostic reagents, and medical devices and equipment primarily in Japan. It offers pharmaceuticals in the fields of neuropsychiatric disorders, allergy, gastrointestinal diseases, dermatology, and central nervous system, as well as treatments for rare diseases and generic drugs. The company also supplies the fecal occult blood test agents and devices that enable tests for the diagnosis of colorectal cancer; offers medical devices, including X-ray machines and MRI machines; and markets diagnostic kits, which aid rapid diagnosis of influenza virus, adenovirus, and other infectious diseases in clinical and nursing settings. In addition, it offers approximately 10,000 varieties of surgical sutures for general surgery, cardiovascular surgery, and plastic surgery, as well as markets a cable system used as wiring material in spinal fusion operations, surgical tools that use microwaves, and other devices. Alfresa Holdings Corporation distributes its products to medical institutions, hospitals and clinics, dispensing pharmacies, drug stores, and other customers through a network of distribution centers.